Business

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer

AstraZeneca

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians

Novartis

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support and facilitate a discussion between physicians and patients living with multiple sclerosis (MS) who have transitioned, or are at risk of transitioning from relapsing remitting MS (RRMS) to secondary progressive MS (SPMS)[1].

Amgen ignites a social fitness movement to support the fight against heart disease and cancer

Amgen

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart DiseaseTM and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class cycling event that takes place May 12 - 18, 2019.

AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery

AstraZeneca

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Bristol-Myers Squibb reports first quarter financial results

Bristol-Myers Squibb

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.

Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis

Pfizer

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee.

Roche reports a strong start in 2019 and raises the outlook for the full-year

Roche

In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra.

Business

More Pharma News ...